Our discussion pivots on discussing innovative strategies, particularly emphasizing the potential of GnRH antagonists as a safer and more effective alternative for managing OHSS risk in this particular patient population. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.